Molecular cytogenetic analysis of immunofluorescence-labeled plasma cells of patients with multiple myeloma enrolled in CMG 2002 clinical trial;Výsledky molekulárně cytogenetické analýzy imunofluorescenčně značených plasmatických buněk u pacientů s mnohočetným myelomem zařazených ve studii CMG 2002

Klinicka Onkologie

Volumn 21, Issue SUPPL., 2008, Pages 204-206

  Zemanova Z ^a   Michalova K ^d   Tajtlova J ^a   Pavlistova L ^a   Oltova A ^b   Filkova H ^b,c   Kuglik P ^c   Nemec P ^c   Holzerova M ^d   Balcarkova J ^d   Jarosova M ^d   Rabasova J ^e   Hruba M ^f   Fischlova H ^f   Spicka I ^a   Gregora, E ^g   Adam, Z ^b   Scudla V ^d   Maisnar, V ^e   Schutzova M ^f   Kralova D ^c   Hajek R ^b,c   more..

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

^d PALACKÝ UNIVERSITY   (Czech Republic)

^e UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^f CHARLES UNIVERSITY   (Czech Republic)

^g CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Chromosomal aberration; Cytogenetics; FISH; Multiple myeloma

Indexed keywords

PROTEIN P53;

ARTICLE; CELL HETEROGENEITY; CELL LABELING; CHROMOSOME 13; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CYTOGENETICS; DISEASE ASSOCIATION; GENE; GENE DELETION; GENE TRANSLOCATION; HUMAN; IGH GENE; IMMUNOFLUORESCENCE TEST; MORBIDITY; MULTIPLE MYELOMA; PLASMA CELL; PREVALENCE; PROGNOSIS;

EID: 54249124694     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Avet-Loiseau H, Attal M, Moreau P, et al.: Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood, 2007 Apr 15;109(8):3489-3495.
2. Avet-Loiseau H., Daviet A., Saunier S., Bataille R: Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. British Journal of Haematology, 2000, 111: 1116-1117.
3. Moreau P, Facon T, Leleu X, et al.: Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002 Sep 1; 100(5): 1579-1583.
4. Smajda NV, Bastard C, Brigaudeau C, et al.: Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001 Oct 1; 98(7): 2229-2238.
5. Stewart AK, Bergsagel PL, Greipp PR, et al.: A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007 Mar;21(3):529-34.
6. Tricot G, Sawyer JR, Jagannath S, et al.: Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplant, J Clin Oncol 1997, 15: 2659-2666.